STOCK TITAN

Precision Optics Announces Pricing of $5.1 Million Offering of Common Stock to Fund Business Expansion

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Precision Optics (NASDAQ: POCI) has announced a registered direct offering of 1,272,500 shares of common stock at $4.00 per share, expected to generate gross proceeds of approximately $5.1 million and net proceeds of about $5.0 million after expenses.

The offering, led by existing stockholders, is scheduled to close around February 21, 2025. The company plans to use the proceeds to repay certain debts, expand facilities to support growth, and for general working capital purposes. The offering is being conducted through an effective shelf registration statement on Form S-3 previously filed with the SEC.

Loading...
Loading translation...

Positive

  • Secured $5.1 million in gross proceeds through stock offering
  • Strong support from existing stockholders leading the offering
  • Funds allocated for debt repayment and facility expansion

Negative

  • Potential dilution for existing shareholders through issuance of 1,272,500 new shares
  • Stock offered at $4.00 per share

News Market Reaction

-3.91%
1 alert
-3.91% News Effect

On the day this news was published, POCI declined 3.91%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

GARDNER, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has entered into securities purchase agreements with institutional and accredited investors for the purchase and sale of 1,272,500 shares of the Company's common stock, par value $0.01 per share, pursuant to a registered direct offering at a purchase price of $4.00 per share, resulting in gross proceeds of approximately $5.1 million, and expected net proceeds of approximately $5.0 million after deducting offering expenses. The Company intends to use the net proceeds from the offering to repay certain indebtedness, expand its facilities to support expected growth and related general working capital purposes.

The closing of the offering, which was led by existing stockholders, is expected to occur on or about February 21, 2025, subject to the satisfaction of customary closing conditions.

This offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-280047) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) and declared effective on June 14, 2024. A prospectus supplement describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Precision Optics Corporation
Founded in 1982, Precision Optics is a vertically integrated optics company primarily focused on leveraging its proprietary micro-optics, 3D imaging and digital imaging technologies to the healthcare and defense/aerospace industries by providing services ranging from new product concept through mass manufacture. Utilizing its leading-edge in-house design, prototype, regulatory and fabrication capabilities as well as its Ross Optical division's high volume world-wide sourcing, inspecting and production resources, the Company is able to design and manufacture next-generation product solutions to the most challenging customer requirements. Within healthcare, Precision Optics enables next generation medical device companies around the world to meet the increasing demands of the surgical community who require more enhanced and smaller imaging systems for minimally invasive surgery as well as 3D endoscopy systems to support the rapid proliferation of surgical robotic systems. In addition to these next generation applications, Precision Optics has supplied top tier medical device companies a wide variety of optical products for decades, including complex endocouplers and specialized endoscopes. The Company is also leveraging its technical proficiency in micro-optics to enable leading edge defense/aerospace applications which require the highest quality standards and the optimization of size, weight and power. For more information, please visit www.poci.com.

About Forward-Looking Statements

This press release contains forward-looking statements within the meaning of U.S. federal securities laws. Such forward-looking statements include, but are not limited to, statements regarding the closing of this offering. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements contained in this press release are based on certain assumptions and analyses made by the management of the Company in light of their respective experience and perception of historical trends, current conditions, and expected future developments and their potential effects on the Company as well as other factors they believe are appropriate in the circumstances. There can be no assurance that future developments affecting the Company will be those anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the parties), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, including risks that the closing conditions for this offering will not be achieved, the demand for the Company's products, global supply chains and economic activity in general and other risks and uncertainties identified in the Company's filings with the SEC. Should one or more of these risks or uncertainties materialize or should any of the assumptions being made prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.

Company Contact:
PRECISION OPTICS CORPORATION
22 East Broadway
Gardner, Massachusetts 01440-3338
Telephone: 978-630-1800

Investor Contact:
LYTHAM PARTNERS, LLC
Robert Blum
Telephone: 602-889-9700
poci@lythampartners.com


FAQ

How much money did Precision Optics (POCI) raise in their February 2025 offering?

Precision Optics raised $5.1 million in gross proceeds through a registered direct offering of common stock.

What is the price per share for POCI's February 2025 stock offering?

The offering price was set at $4.00 per share.

How many new shares will POCI issue in the February 2025 offering?

Precision Optics will issue 1,272,500 shares of common stock.

What will POCI use the proceeds from the February 2025 offering for?

The proceeds will be used to repay certain indebtedness, expand facilities to support growth, and for general working capital purposes.

When is POCI's February 2025 stock offering expected to close?

The offering is expected to close on or about February 21, 2025.
Precision Optics

NASDAQ:POCI

POCI Rankings

POCI Latest News

POCI Latest SEC Filings

POCI Stock Data

40.04M
5.55M
18.29%
34.31%
0.71%
Medical Instruments & Supplies
Electromedical & Electrotherapeutic Apparatus
Link
United States
GARDNER